SEC Form 4 · accession 0001178913-18-000894
Artemis Therapeutics, Inc. · ATMS
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Chanan Morris
Officer — Chief Financial Officer
Period of report
Mar 15, 2018
Accepted (ET)
Mar 19, 2018 · 4:15 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001062128
Table I — non-derivative securities
No Table I lines on this filing.
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option (Right to Buy)F1 | $1.30 | Mar 15, 2018 | A | 50,000 | A | — | Mar 15, 2028 | Common Stock | 50,000 | 50,000 | D |
Explanation of responses
- F1The option, representing a right to purchase 50,000 shares of the Issuer's common stock at an exercise price of $1.30 per share, vests ratably over a 48 month period commencing on the first day of the month beginning on February 1, 2018.